Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting
Background: Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
SAGE Publishing,
2023-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|